Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Inrebic Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.25

    Inrebic (fedratinib) Coverage Policy

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.25 alerts

    Get alerted when Policy 05.05.25 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Inrebic (fedratinib) in members being treated for specified myelofibrosis, myeloproliferative neoplasms, and myeloid/lymphoid neoplasms. Coverage requires an eligible diagnosis and satisfaction of applicable initial or continuation criteria, subject to plan benefits and exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyInrebic (fedratinib) Coverage Policy
    Policy CodePolicy 05.05.25
    Change TypeNo material clinical or coverage change
    Effective DateSep 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation, including testing or analysis confirming JAK2 rearrangement when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization period
    12 monthsContinuation authorization period
    120 capsulesQuantity limit for 100 mg capsules
    400 mg dailyFDA-recommended dosing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Listed compendial-use categories

    Coverage Criteria

    Initial Therapy: Myelofibrosis/Myeloproliferative Neoplasms

    Authorization of 12 months may be granted when ALL of the following are met:

    ONE of the following

    • Myelofibrosis

      • Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
      • Splenomegaly and other disease-related symptoms of MF-associated anemia (e.g., fatigue, weakness, shortness of breath, pale skin).
    • Accelerated phase or blast phase myeloproliferative neoplasms.

    Initial Therapy: Myeloid/Lymphoid Neoplasms

    Authorization of 12 months may be granted when the following criterion is met:

    Diagnosis of myeloid and/or lymphoid neoplasms with eosinophilia and JAK2 rearrangement in the chronic phase or blast phase.

    Continuation Therapy: Myelofibrosis/Myeloproliferative Neoplasms

    Authorization of 12 months may be granted for continued treatment when ALL of the following are met:

    ALL of the following

    • The member is requesting reauthorization for continued treatment.
    • There is no evidence of unacceptable toxicity.
    • There has been an improvement in symptoms.

    Continuation Therapy: Myeloid/Lymphoid Neoplasms

    Authorization of 12 months may be granted for continued treatment when ALL of the following are met:

    ALL of the following

    • The member is requesting reauthorization for continued treatment.
    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.

    Coverage is subject to exclusions applicable to the prescribed therapy.

    Inrebic (fedratinib) is considered not medically necessary for members who do not meet the criteria set forth above.

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Submission Required

    Submit the required information to initiate prior authorization review for Inrebic (fedratinib), including documentation of applicable testing or analysis confirming JAK2 rearrangement.

    Documentation Required

    JAK2 Rearrangement Documentation Required

    For applicable indications, provide testing or analysis documentation confirming JAK2 rearrangement as part of the prior authorization submission.

    Denial Risk

    Criteria Not Met

    Clinical Background

    Inrebic (fedratinib) is covered for selected adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Covered clinical uses also include myeloid, lymphoid, or mixed-lineage neoplasms with eosinophilia and a JAK2 rearrangement, myeloproliferative neoplasms in accelerated or blast phase, and splenomegaly with other disease-related symptoms of myelofibrosis-associated anemia. Continued treatment requires clinical benefit or disease control without unacceptable toxicity.

    Initial Therapy Criteria

    Initial Myelofibrosis/Myeloproliferative Neoplasm Criteria

    Authorization of 12 months may be granted for myelofibrosis/myeloproliferative neoplasms when the member has an eligible diagnosis.

    Eligible myelofibrosis/myeloproliferative neoplasm indication

    • MF-associated anemia indication

      • The member has splenomegaly and other disease-related symptoms of MF-associated anemia, such as fatigue, weakness, shortness of breath, or pale skin.
    • The member has intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia myelofibrosis.Intermediate-2 or high risk
    • The member has an accelerated-phase or blast-phase myeloproliferative neoplasm.Accelerated phase or blast phase

    Continuation Therapy Criteria

    Continuation Myelofibrosis/Myeloproliferative Neoplasm Criteria

    Authorization of 12 months may be granted for continued treatment of myelofibrosis/myeloproliferative neoplasms.

    Continued myelofibrosis/myeloproliferative neoplasm therapy

    • There is no evidence of unacceptable toxicity.
    • There has been an improvement in symptoms.Symptom improvement

    Continuation Myeloid/Lymphoid Neoplasm Criteria

    Authorization of 12 months may be granted for continued treatment of myeloid/lymphoid neoplasms.

    Continued myeloid/lymphoid neoplasm therapy

    Quantity Limits and Dosing

    Quantity Limits
    MedicationInrebic (fedratinib) 100 mg capsule
    Quantity limit120 capsules per 30 days
    FDA-recommended dosing400 mg orally once daily
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyInrebic (fedratinib) Coverage Policy
    Policy CodePolicy 05.05.25
    Change TypeNo material clinical or coverage change
    Effective DateSep 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation, including testing or analysis confirming JAK2 rearrangement when applicable.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and DocumentationClinical BackgroundInitial Therapy CriteriaContinuation Therapy CriteriaQuantity Limits and Dosing

    Inrebic (fedratinib) is considered not medically necessary for members who do not meet the criteria set forth in the policy.

    Denial Risk

    No Applicable Therapy Exclusions

    Coverage is available only when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.

    Initial Myeloid/Lymphoid Neoplasm Criteria

    Authorization of 12 months may be granted for myeloid/lymphoid neoplasms.

    Eligible myeloid/lymphoid neoplasm: The member has a myeloid and/or lymphoid neoplasm with eosinophilia and JAK2 rearrangement in the chronic phase or blast phase.Chronic phase or blast phase

    Documentation confirming JAK2 rearrangement is required when applicable.

    There is no evidence of unacceptable toxicity.
  1. There is no evidence of disease progression while the member is receiving the current regimen.No disease progression on the current regimen